Mediterranean Diet and Mild Cognitive Impairment by Scarmeas, Nikolaos et al.
ORIGINAL CONTRIBUTION
Mediterranean Diet and Mild Cognitive Impairment
Nikolaos Scarmeas, MD; Yaakov Stern, PhD; Richard Mayeux, MD;
Jennifer J. Manly, PhD; Nicole Schupf, PhD; Jose A. Luchsinger, MD
Background: Higher adherence to the Mediterranean
diet (MeDi) may protect from Alzheimer disease (AD),
but its association with mild cognitive impairment (MCI)
has not been explored.
Objective: To investigate the association between the
MeDi and MCI.
Design, Setting, and Patients: In a multiethnic com-
munity study in New York, we used Cox proportional haz-
ards to investigate the association between adherence to
the MeDi (0-9 scale; higher scores indicate higher adher-
ence) and (1) the incidence of MCI and (2) the progres-
sion from MCI to AD. All of the models were adjusted for
cohort, age, sex, ethnicity, education,APOE genotype, ca-
loric intake, body mass index, and duration between base-
line dietary assessment and baseline diagnosis.
Main OutcomeMeasures: Incidence of MCI and pro-
gression from MCI to AD.
Results: There were 1393 cognitively normal partici-
pants, 275 of whom developed MCI during a mean (SD)
follow-up of 4.5 (2.7) years (range, 0.9-16.4 years). Com-
pared with subjects in the lowest MeDi adherence tertile,
subjects in the middle tertile had 17% less risk (hazard
ratio [HR]=0.83; 95% confidence interval [CI], 0.62-
1.12; P=.24) of developing MCI and those in the high-
est tertile had 28% less risk (HR=0.72; 95% CI, 0.52-
1.00; P=.05) of developing MCI (trend HR=0.85; 95%
CI, 0.72-1.00; P for trend=.05). There were 482 sub-
jects with MCI, 106 of whom developed AD during a mean
(SD) follow-up of 4.3 (2.7) years (range, 1.0-13.8 years).
Compared with subjects in the lowest MeDi adherence
tertile, subjects in the middle tertile had 45% less risk
(HR=0.55; 95% CI, 0.34-0.90; P=.01) of developing AD
and those in the highest tertile had 48% less risk
(HR=0.52; 95% CI, 0.30-0.91; P=.02) of developing AD
(trend HR=0.71; 95% CI, 0.53-0.95; P for trend=.02).
Conclusions: Higher adherence to the MeDi is associ-
ated with a trend for reduced risk of developing MCI and
with reduced risk of MCI conversion to AD.
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T HE CONCEPT OF MILD COG-nitive impairment (MCI)was developed to identifysubjects who are in thetransitional stage between
normal aging and dementia or Alzheimer
disease (AD). Because of the high conver-
sion rates, subjects with MCI constitute a
population suited for study of demen-
tia-AD risk factor epidemiology and for in-
vestigation of possible behavioral or phar-
macological preventive interventions.
Among behavioral traits, diet may play an
important role in the cause and preven-
tion of AD. However, epidemiological data
on diet and AD have been conflicting.1,2
Moreover, there is a paucity of research on
the effect of dietary factors on both rates
of development of MCI and rates of MCI
conversion to AD.
We recently demonstrated that higher
adherence to the Mediterranean diet
(MeDi) (a diet characterized by high in-
take of fish, vegetables, legumes, fruits, ce-
reals, and unsaturated fatty acids [mostly
in the form of olive oil], low intake of dairy
products, meat, and saturated fatty acids,
and a regular but moderate intake of al-
cohol3) is associated with lower AD risk.4,5
Some studies have investigated the effect
of individual elements of the MeDi (ie, al-
cohol, fatty acids, and fish) in MCI and age-
related cognitive decline6-12 and have found
conflicting results. Nevertheless, poten-
tial associations between the entire MeDi
pattern and MCI have not been explored.
We examined the association between the
MeDi and MCI using data from the Wash-
ington Heights–Inwood Columbia Aging
Project (WHICAP). We hypothesized that
cognitively normal participants with higher
adherence to the MeDi would have a lower
risk of future development of MCI and that
participants with MCI and higher MeDi ad-
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METHODS
SAMPLE AND DIAGNOSES
The sample for the current study has been described in detail in
recent studies exploring the frequency and course of MCI in our
cohorts.13,14 The study included participants of 2 related co-
horts recruited in 1992 (WHICAP 1992) and 1999 (WHICAP
1999) who were identified (via ethnicity and age stratification
processes) from a probability sample of Medicare beneficiaries
residing in an area of 3 contiguous census tracts within a geo-
graphically defined area of northern Manhattan, New York.15 The
same assessments and study procedures were used in both co-
horts. At entry, a physician elicited each subject’s medical and
neurological history and conducted a standardized physical and
neurological examination. All available ancillary information
(medical records, computed tomographic scans, or magnetic reso-
nance images) was considered in the evaluation.
Each subject also underwent a structured in-person inter-
view including an assessment of health and function and a neu-
ropsychological battery. Functional assessment of instrumental
activities of daily living included a disability and functional limi-
tations scale.16,17 The neuropsychological battery18 contained tests
of memory (short- and long-term verbal and nonverbal), orien-
tation, abstract reasoning (verbal and nonverbal), language (nam-
ing, verbal fluency, comprehension, and repetition), and con-
struction (copying and matching). A global summary score on
the Clinical Dementia Rating (CDR)19 was also assigned.
A consensus diagnosis for the presence or absence of demen-
tia was made at a diagnostic conference of neurologists and neu-
ropsychologists where information of all the above evaluations
was presented. Evidence of cognitive deficit (based on the neu-
ropsychological scores as described earlier), evidence of impair-
ment in social or occupational function (as assessed by the Blessed
Dementia Rating Scale, the Schwab and England Activities of Daily
Living Scale, and the physician’s assessment), and evidence of
cognitive and social-occupational function decline were the cri-
teria used for the diagnosis of dementia as required by the Di-
agnostic and StatisticalManual ofMental Disorders, Revised Third
Edition.20 The type of dementia was subsequently determined.
For the diagnosis of probable or possible AD, the criteria of the
National Institute of Neurological and Communicative Disor-
ders and Stroke–Alzheimer Disease and Related Disorders As-
sociation21 were used.
Because the current study had started before the concept of
MCI was developed, diagnosis of MCI was not part of the stan-
dard consensus conference procedure but was retrospectively ap-
plied after the consensus conference for each visit among non-
demented individuals. Details on the MCI definition have been
previously provided.13,14 Briefly, consistent with standard crite-
ria,22 subjects considered for MCI were required to have the fol-
lowing. First, they had a subjective memory complaint (using
items from the Disability and Functional Limitations Scale16,17
and the Blessed Functional Activities Scale23). Second, they had
objective impairment in at least 1 cognitive domain. Using se-
lected items from the neuropsychological battery, 4 cognitive do-
mains (memory, executive, language, and visuospatial) were de-
fined.13,14 Impairment was defined based on the average of the
scores on the neuropsychological measures within that domain
and a 1.5-SD cutoff using corrections for age, years of educa-
tion, ethnicity, and sex and based on the previously established
norms. Third, they had essentially preserved activities of daily
living (defined earlier). Fourth, they had no diagnosis of demen-
tia at the consensus conference. To further explore the associa-
tion of the MeDi to MCI, in the view of the original criteria by
Petersen et al22,24 (which focus on objective memory impair-
ment), the overall MCI group was divided into 2 mutually ex-
clusive MCI subtypes: (1) MCI with objective memory impair-
ment (with or without objective impairment in other cognitive
domains), and (2) MCI without objective memory impairment
(objective impairment in1 of the 3 nonmemory domains but
a memory domain composite score within norms). Dietary data
were not available to the consensus panel and were not consid-
ered in the MCI diagnostic process. Subjects were followed up
at intervals of approximately 1.5 years, repeating the baseline ex-
amination and consensus diagnosis at each follow-up.
PREDICTORS
Diet
Dietary data regarding average food consumption during the past
year were obtained using a 61-item version of the semiquantita-
tive food frequency questionnaire by Willett et al25 (Channing
Laboratory, Cambridge, Massachusetts). Trained interviewers ad-
ministered the semiquantitative food frequency questionnaire in
English or Spanish. We have previously reported validity (using
two 7-day food records) and reliability (using two 3-month fre-
quency assessments) of various components of the semiquanti-
tative food frequency questionnaire in the WHICAP.26-28
Similar to our previous work,4,5,29 we followed a method pre-
viously described3 for the construction of the MeDi score. More
specifically, we first regressed caloric intake (in kilocalories) and
calculated the derived residuals of daily gram intake30 for each of
the following 7 categories3: dairy, meat, fruits, vegetables, le-
gumes, cereals, and fish. A value of 0 or 1 was assigned to each of
the 7 groups using sex-specific medians as cutoffs. For benefi-
cial components (fruits, vegetables, legumes, cereals, and fish),
persons whose consumption was below the median were as-
signed a value of 0 and persons whose consumption was at or
above the median were assigned a value of 1. For components
presumed to be detrimental (meat and dairy products), persons
whose consumption was below the median were assigned a value
of 1 and persons whose consumption was at or above the me-
dian were assigned a value of 0. For fat intake (eighth food cat-
egory), we used the ratio of daily consumption (in grams) of mono-
unsaturated lipids to saturated lipids3 (again using sex-specific
median cutoffs for assignment values of 0 for low and 1 for high).
For alcohol intake (ninth food category), subjects were assigned
a score of 0 for either no consumption (0 g/d) or more than mod-
erate consumption (30 g/d) and a value of 1 for mild to mod-
erate alcohol consumption (0 to 30 g/d). This is in agree-
ment with previous reports3 that consider a moderate amount of
alcohol consumption as another characteristic component of the
MeDi. We also classified alcohol consumption dichotomously be-
cause of the skewed distribution of alcohol consumption in our
population (68% reporting no alcohol intake, 31% reporting30
g/d [mild to moderate intake], and 1% reporting30 g/d [heavy
intake]). The MeDi score was generated for each participant by
adding the scores in the food categories (theoretically ranging from
0-9) with a higher score indicating higher adherence to the MeDi.
We used the MeDi score from the first time the dietary as-
sessment was performed as the main predictor in the survival
analyses. Because the cognitively normal and MCI definitions were
partly based on availability of neuropsychological assessments,
their ascertainment was not always synchronous with the di-
etary assessments. For the incident MCI analyses, the time of the
first dietary assessment coincided (±1.5 years) with the time of
the first assessment of cognitively normal status for 82% of the
subjects, was more than 1.5 years earlier for 14% of the sub-
jects, and was more than 1.5 years later for only 4%. For the in-
cident AD analyses, the time of the first dietary assessment co-
incided (±1.5 years) with the time of the first assessment of MCI
status for 84% of the subjects, was more than 1.5 years earlier
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for 11% of the subjects, and was more than 1.5 years later for
only 5%. To summarize, the timing of the MeDi adherence as-
sessment and the cognitively normal or MCI assessments over-
lapped to a significant degree. Despite this, in all of the survival
models we included a term adjusting for the difference in the
time between the first dietary assessment and the first cognitive
status assessment.
Covariates
Age (in years), education (in years), caloric intake (in kilocalo-
ries), and body mass index (BMI) (weight in kilograms divided
by height in meters squared)31 were used as continuous vari-
ables. We also considered cohort (1992 cohort as the reference)
and sex (men as the reference). Ethnic group was based on self-
report using the format of the 1990 census.32 Participants were
then assigned to 1 of 4 groups: black (non-Hispanic), Hispanic,
white (non-Hispanic), or other. Ethnicity was used as a dummy
variable with white (non-Hispanic) as the reference. Apolipopro-
tein E (APOE) genotype was used dichotomously: absence of the
ε4 allele vs presence of either 1 or 2 ε4 alleles.
STATISTICAL ANALYSES
Baseline characteristics of subjects by missing dietary data, by
outcome of interest, and by MeDi adherence tertiles were com-
pared using t test or analysis of variance for continuous vari-
ables and 2 test for categorical variables.
Cognitively Normal to Incident MCI
We calculated Cox proportional hazards models with MCI as
the dichotomous outcome. The time-to-event variable was the
time from the first cognitively normal status to the first visit
with an MCI diagnosis. Subjects diagnosed with MCI and then
reverting back to normal were considered cases, and their first
MCI diagnostic visit was considered the event visit. Persons who
did not develop MCI were censored at the time of their last fol-
low-up (ie, all subject visits before the last follow-up were used
in the analyses). The main predictor was the MeDi score (from
the first dietary evaluation) as a continuous variable initially
and in tertiles subsequently (used for trend test calculation).
We simultaneously adjusted for the following variables: co-
hort, age at intake in the study, sex, ethnicity, education, APOE
genotype, BMI, and time between the first dietary assessment
and the first cognitive status assessment. Although caloric intake–
adjusted residuals were used in the MeDi score calculation, we
also included caloric intake as a covariate in the models (as rec-
ommended by Willett and Stampfer30). All of the predictors were
used as time-constant covariates. In additional analyses, we re-
calculated the models using the 2 different types of MCI as the
outcomes: with and without memory impairment.
MCI to Incident AD
We calculated Cox proportional hazards models with AD as
the dichotomous outcome. The time-to-event variable was the
time from the first MCI status to the first visit with an AD di-
agnosis. Subjects diagnosed with AD and then reverting back
to MCI were considered cases, and their first AD diagnostic visit
was considered the event visit. Therefore, censored subjects never
developed AD at any of their follow-up visits. Persons who did
not develop AD were censored at the time of their last fol-
low-up (ie, all of the subject visits before the last follow-up were
used in the analyses). Predictors and covariates were the same
as in the earlier-described models for cognitively normal to in-
cident MCI. In additional analyses, we recalculated the mod-
els using the 2 different types of MCI (with and without memory
impairment) as the starting point.
RESULTS
MISSING DATA ANALYSES
Among all of the potential participants in both WHICAP
cohorts, 2364 individuals were considered for this study
because of sufficient data for MCI diagnosis and available
follow-up14 (Figure1). As previously reported,14 in com-
parison with 1329 subjects who were not considered be-
cause of missing data or lack of follow-up, these 2364 sub-
jects were slightly younger, were more likely to be women,
and had higher cognitive performance but did not differ
in ethnicity. Among the 2364 subjects, 1800 were cogni-
tively normal (nondemented, non-MCI) at the initial evalu-
ation (serving for calculation of the effect of the MeDi on
the incidence of MCI) and 564 were diagnosed with MCI
at the initial evaluation (serving for calculation of the effect
of the MeDi on the MCI conversion to AD).
Cognitively Normal to Incident MCI Analyses
Among the 1800 subjects who were cognitively normal
at the initial evaluation, dietary information was missing
for 184 subjects (partly because the dietary assessment com-
ponent was added after initiation of the study) (Figure 1).
To have an even cleaner sample for the incident MCI analy-
ses, we additionally excluded 223 subjects who, despite
not meeting our MCI criteria, had a CDR of 0.5 at the first
evaluation. Compared with the 184 subjects with miss-
ing dietary information, the 1393 cognitively normal sub-
jects (with a CDR of 0.0 and available dietary informa-
tion) used for the incident MCI analyses had lower BMIs
(28.5 vs 27.5, respectively; P=.02) and borderline higher
cognitive performance (composite cognitive z score, 0.37
vs 0.46, respectively; P=.05). The groups did not differ in
sex, age, ethnicity, education, or APOE status. As ex-
pected, compared with the 223 subjects with a CDR of 0.5,
the 1393 cognitively normal subjects (with a CDR of 0.0
and available dietary information) used for the incident
MCI analyses were younger (79.0 vs 76.7 years, respec-
tively; P .001), were more educated (6.8 vs 10.8 years


















Figure 1. Flowchart describing the sample. MCI indicates mild cognitive
impairment; CDR, Clinical Dementia Rating.
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formance (composite cognitive z score, −0.46 vs 0.46, re-
spectively;P.001), and were more likely to be white (11%
vs 31%, respectively) and less likely to be Hispanic (60%
vs 34%, respectively) (P .001). The groups did not dif-
fer in sex, BMI, or APOE status.
MCI to Incident AD Analyses
Compared with the 82 subjects with MCI and missing
dietary information, the 482 subjects with MCI and avail-
able dietary information included in the incident AD
analyses had borderline higher education (8.0 vs 9.1 years
of school, respectively; P=.05) and borderline higher cog-
nitive performance (composite cognitive z score, −0.40
vs −0.27, respectively; P=.05). The groups did not dif-
fer in sex, age, ethnicity, APOE status, or BMI.
CLINICAL, DEMOGRAPHIC,
AND DIETARY CHARACTERISTICS
At the first evaluation, compared with subjects who were
cognitively normal, subjects with MCI were older, less
educated, more likely to be Hispanic, and less likely to
be white (Table1). Cognitively normal subjects and sub-
jects with MCI did not differ in sex,APOE genotype, BMI,
total caloric intake, and MeDi adherence.
Hispanic subjects adhered more to the MeDi, black
subjects adhered less, and white subjects’ adherence was
in between (Table 2). The higher the MeDi adherence
was, the lower the total caloric intake was. There was no
association between the MeDi score and age, sex, edu-
cation, APOE genotype, or BMI.
MeDi AND RISK FOR INCIDENT MCI
Despite somewhat lower scores in subjects with MCI (as
compared with cognitively normal subjects) at baseline
(Table 1), the groups did not significantly differ cross-
sectionally. Longitudinal analyses (particularly with use
of survival models) are a much more powerful method
of detecting predictor differences because they can com-
bine in a single statistic 2 different risk dimensions: (1)
the proportion of subjects who reach an event (convert
to MCI or AD), and (2) duration (how soon subjects con-
vert or nonconvert to MCI or AD).








Men, No. (%) 447 (32) 156 (32) 603 (32) .91
Age, mean (SD), y 76.7 (6.5) 77.5 (6.6) 76.9 (6.5) .02
Ethnicity, No. (%)
White 434 (31) 124 (26) 558 (30)
.001
Black 479 (34) 144 (30) 623 (33)
Hispanic 473 (34) 214 (44) 687 (36)
Other 7 (1) 0 7 (1)
Education, mean (SD), y 10.8 (4.6) 9.1 (4.9) 10.4 (4.7) .001
1 ε4 allele, No. (%) 327 (27) 127 (30) 454 (28) .18
BMI, mean (SD) 27.5 (5.5) 27.2 (5.3) 27.4 (5.4) .34
Energy, mean (SD), kcal 1426.1 (498.0) 1421.8 (591.9) 1425.0 (523.6) .88
MeDi score, mean (SD) 4.37 (1.69) 4.31 (1.62) 4.36 (1.67) .47
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MCI, mild cognitive impairment;
MeDi, Mediterranean diet.
Table 2. Demographic and Clinical Characteristics During the First Evaluation for All Subjects










Men, No. (%) 442 (69) 532 (69) 318 (65) .23
Age, mean (SD), y 76.9 (6.6) 76.8 (6.5) 77.2 (6.2) .48
Ethnicity, No. (%)
White 182 (30) 223 (29) 153 (31)
.001
Black 234 (38) 260 (33) 139 (26)
Hispanic 190 (31) 289 (37) 208 (42)
Other 3 (1) 3 (1) 1 (1)
Education, mean (SD), y 10.5 (4.5) 10.3 (4.7) 10.4 (4.9) .77
1 ε4 allele, No. (%) 146 (27) 179 (27) 129 (29) .70
BMI, mean (SD) 27.7 (5.8) 27.4 (5.2) 27.1 (5.3) .19
Energy, mean (SD), kcal 1494.9 (608.2)a 1395.4 (472.5)a 1385.1 (477.4)a .001
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MeDi, Mediterranean diet.
aP .05 for all MeDi adherence tertiles according to post hoc Scheffé test.
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Subjects who were cognitively normal at the first evalu-
ation were followed up (until MCI incidence or the last
follow-up for subjects who remained cognitively nor-
mal) for a mean (SD) of 4.5 (2.7) years (range, 0.9-16.4
years). Overall, 275 subjects developed incident MCI.
Higher adherence to the MeDi was associated with a
borderline trend for lower risk of developing MCI
(Table 3 and Figure 2). The results were similar in
adjusted and unadjusted models. Each additional unit of
the MeDi score was associated with 8% less risk (P=.04)
of developing MCI. Compared with subjects in the low-
est MeDi adherence tertile, subjects in the middle tertile
had 17% less risk (P=.24) of developing MCI and those
in the highest tertile had 28% less risk (P=.05) of devel-
oping MCI. Among the other covariates in the model,
younger age and higher education were the only protec-
tive factors for development of MCI.
The effect of the MeDi on development of different
MCI subtypes is subject to power limitations but is still
worth exploring. Overall, 108 subjects developed inci-
dent MCI with memory impairment. In fully adjusted
models, as compared with subjects in the lowest MeDi
adherence tertile, those in the middle tertile had a haz-
ard ratio (HR) of 0.90 (95% confidence interval [CI], 0.57-
1.40; P=.64) for developing MCI with memory impair-
ment, whereas those in the highest tertile had an HR of
0.71 (95% CI, 0.43-1.17; P=.18). The overall MeDi HR
trend was 0.84 (95% CI, 0.66-1.03; P for trend=.18). A
total of 133 subjects developed MCI without memory im-
pairment. In fully adjusted models, as compared with sub-
jects in the lowest MeDi adherence tertile, those in the
middle tertile had an HR of 0.79 (95% CI, 0.53-1.19;
P=.27) for developing MCI without memory impair-
ment and those in the highest tertile had an HR of 0.71
(95% CI, 0.46-1.12; P=.14). The overall MeDi HR trend
was 0.84 (95% CI, 0.67-1.05; P for trend=.13).
MeDi AND RISK FOR MCI CONVERSION TO AD
Subjects with MCI at the first evaluation were followed up
(until AD incidence or last follow-up for subjects who did
not develop AD) for a mean (SD) of 4.3 (2.7) years (range,
1.0-13.8 years). Overall, 106 subjects developed AD.
Higher adherence to the MeDi was associated with lower
risk of developing AD (Table 4 and Figure 3). The re-
sults were similar in adjusted and unadjusted models. Each
additional unit of the MeDi score was associated with 11%
less risk (P=.09) of developing AD. Compared with sub-
jects in the lowest MeDi adherence tertile, subjects in the
middle tertile had 45% less risk (P=.01) of developing AD
and those in the highest tertile had 48% less risk (P=.02)
of developing AD. Among the other covariates in the model,
younger age, higher education, and higher BMI were the
only protective factors for development of AD.
At the first evaluation, 175 subjects had MCI with
memory impairment; 49 of them developed AD at follow-
up. In fully adjusted models, as compared with subjects
who had MCI with memory impairment belonging to the
lowest MeDi adherence tertile, those who had MCI with
memory impairment in the middle tertile had an HR of
0.48 (95% CI, 0.22-1.04; P=.06) for developing AD and
those who had MCI with memory impairment in the high-
est tertile had an HR of 0.71 (95% CI, 0.32-1.59; P=.41).
The overall MeDi HR trend was 0.84 (95% CI, 0.55-
1.29; P for trend=.45). At the first evaluation, 234 sub-
jects had MCI without memory impairment; 47 of them
developed AD at follow-up. In fully adjusted models, as
Table 3. Cox Proportional Hazard Ratios for Incidence
of Mild Cognitive Impairment for Subjects Who Were
Cognitively Normal at the First Evaluation
by Mediterranean Diet Score
Predictor HR (95% CI) P Value
Unadjusteda
MeDi continuous 0.93 (0.87-1.00) .06
MeDi tertile
Low 1 [Reference] NA
Middle 0.87 (0.66-1.14) .33
High 0.73 (0.53-1.00) .05
Trend 0.85 (0.73-1.00) .05
Adjustedb
MeDi continuous 0.92 (0.85-0.99) .04
MeDi tertile
Low 1 [Reference] NA
Middle 0.83 (0.62-1.12) .24
High 0.72 (0.52-1.00) .05
Trend 0.85 (0.72-1.00) .05
Abbreviations: CI, confidence interval; HR, hazard ratio;
MeDi, Mediterranean diet; NA, not applicable.
aA total of 1393 subjects were cognitively normal at the first evaluation;
275 subjects developed incident mild cognitive impairment.
bA total of 1199 subjects were cognitively normal at the first evaluation;
241 subjects developed incident mild cognitive impairment. Adjusted models
include a slightly lower number of subjects because of missing data in some
of the covariates; they simultaneously control for cohort, age, sex, ethnicity,
education, APOE genotype, caloric intake, body mass index, and time
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Figure 2. Survival curves based on Cox analysis comparing cumulative mild
cognitive impairment (MCI) incidence in subjects who were cognitively
normal at the first evaluation by each Mediterranean diet (MeDi) adherence
tertile (P for trend=.05). The figure is derived from a model that is adjusted
for cohort, age, sex, ethnicity, education, APOE genotype, caloric intake,
body mass index, and time between the first dietary assessment and the first
cognitive assessment. Duration of follow-up is truncated at 10 years. Results
of log-rank tests for pairwise comparisons are as follows: middle vs low
tertile, 2=0.91, P=.33; low vs high tertile, 2=3.72, P=.05; and middle vs
high tertile, 2=1.22, P=.26.
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compared with subjects who had MCI without memory
impairment in the lowest MeDi adherence tertile, those
who had MCI without memory impairment in the middle
tertile had an HR of 0.49 (95% CI, 0.24-1.01; P=.05) for
developing AD and those who had MCI without memory
impairment in the highest tertile had an HR of 0.25 (95%
CI, 0.10-0.63; P=.003). The overall MeDi HR trend was
0.50 (95% CI, 0.35-0.79; P for trend=.003).
SUPPLEMENTARY ANALYSES
Considering the possibility of an overall healthier life-
style behavior accounting for the MeDi effect, we consid-
ered a measure of overall comorbidity in the analyses: a
modified version33,34 of the Charlson Index of Comorbid-
ity.35 This measure includes items for myocardial infarct,
congestive heart failure, peripheral vascular disease, hy-
pertension, chronic renal disease, chronic obstructive pul-
monary disease, arthritis, gastrointestinal disease, mild liver
disease, diabetes, and systemic malignant neoplasms. There
was no difference in comorbidity index between subjects
who remained cognitively normal during follow-up and
those who developed MCI during follow-up (1.9 vs 1.9,
respectively;P=.91) or between those who had MCI at base-
line and those who developed AD during follow-up (2.0
vs 2.1, respectively; P=.66). Similarly, the comorbidity in-
dex did not differ between levels of MeDi adherence: 1.9
for the lowest tertile, 1.9 for the middle tertile, and 1.9 for
the highest tertile (P=.75). Including the comorbidity in-
dex (simultaneously with all of the other covariates) in the
incident MCI analyses did not appreciably change the re-
sults: the middle MeDi adherence tertile had an HR of 0.83
(95% CI, 0.61-1.12; P=.23), the highest tertile had an HR
of 0.74 (95% CI, 0.53-1.04; P=.08), and the overall MeDi
tertile HR trend was 0.86 (95% CI, 0.72-1.02; P for
trend=.08). Including the comorbidity index (simulta-
neously with all of the other covariates) in the incident
AD analyses produced similar results: the middle tertile
had an HR of 0.59 (95% CI, 0.36-0.97; P=.04), the high-
est tertile had an HR of 0.56 (95% CI, 0.32-0.97; P=.04),
and the overall MeDi tertile HR trend was 0.74 (95% CI,
0.55-0.98; P for trend=.04).
In additional supplementary analyses, we used age
(rather than duration from cognitive assessment) as the
time-to–incident MCI variable. In these analyses, the di-
rectionality of the effect was similar but the strength was
significantly attenuated: the continuous MeDi HR was
0.94 (95% CI, 0.87-1.0; P=.09), the middle MeDi adher-
ence tertile had an HR of 0.91 (95% CI, 0.69-1.19; P=.49),
the highest tertile had an HR of 0.76 (95% CI, 0.56-
1.04; P=.09), and the overall MeDi tertile HR trend was
0.87 (95% CI, 0.75-1.02; P for trend=.09).
COMMENT
This study suggests that higher adherence to the MeDi is
associated with a borderline reduction in the risk of de-
veloping MCI and a reduction in the risk of conversion
from MCI to AD. The gradual reduction in risks for higher
tertiles of MeDi adherence also suggests a possible dose-
response effect. The associations between MeDi and the
risk of developing MCI and of MCI conversion to AD did
not attenuate even when simultaneously adjusting for many
commonly considered potential confounders such as age,
Table 4. Cox Proportional Hazard Ratios for Incidence
of Alzheimer Disease for Subjects With Mild Cognitive
Impairment at the First Evaluation
by Mediterranean Diet Score
Predictor HR (95% CI) P Value
Unadjusteda
MeDi continuous 0.95 (0.85-1.07) .48
MeDi tertile
Low 1 [Reference] NA
Middle 0.62 (0.39-0.98) .04
High 0.69 (0.41-1.14) .15
Trend 0.82 (0.63-1.07) .15
Adjustedb
MeDi continuous 0.89 (0.78-1.02) .09
MeDi tertile
Low 1 [Reference] NA
Middle 0.55 (0.34-0.90) .01
High 0.52 (0.30-0.91) .02
Trend 0.71 (0.53-0.95) .02
Abbreviations: CI, confidence interval; HR, hazard ratio;
MeDi, Mediterranean diet; NA, not applicable.
aA total of 482 subjects had mild cognitive impairment at the first
evaluation; 106 subjects developed incident Alzheimer disease.
bA total of 409 subjects had mild cognitive impairment at the first
evaluation; 96 subjects developed incident Alzheimer disease. Adjusted
models include a slightly lower number of subjects because of missing data
in some of the covariates; they simultaneously control for cohort, age, sex,
ethnicity, education, APOE genotype, caloric intake, body mass index, and
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Figure 3. Survival curves based on Cox analysis comparing cumulative
Alzheimer disease (AD) incidence in subjects with mild cognitive impairment
(MCI) at the first evaluation by Mediterranean diet (MeDi) adherence tertile
(P for trend=.02). The figure is derived from a model that is adjusted for
cohort, age, sex, ethnicity, education, APOE genotype, caloric intake, body
mass index, and time between the first dietary assessment and the first
cognitive assessment. Duration of follow-up is truncated at 10 years. Results
of log-rank tests for pairwise comparisons are as follows: middle vs low
tertile, 2=4.26, P=.03; low vs high tertile, 2=1.39, P=.23; and middle vs
high tertile, 2=0.12, P=.72.
(REPRINTED) ARCH NEUROL / VOL 66 (NO. 2), FEB 2009 WWW.ARCHNEUROL.COM
221
©2009 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a Columbia University User  on 01/28/2016
sex, ethnicity, education, APOE genotype, caloric intake,
and BMI. Adherence to the MeDi did not seem to differ-
entially affect the risk of development of MCI with or with-
out memory impairment. The association between higher
adherence to the MeDi and lower risk of conversion to AD
was much more prominent for subjects who had MCI with-
out memory impairment.
Higher adherence to the MeDi has been related to lower
risk of AD.4,5 Mild cognitive impairment has been de-
scribed as a predictor or a transitional stage between nor-
mal cognition and AD.36,37 Thus, we expected that higher
adherence to the MeDi would be related to MCI. The as-
sociation between adherence to the MeDi and MCI in-
cidence was similar for MCI with and without memory
impairment, whereas the protective MeDi effect for AD
conversion was stronger for subjects who had MCI with-
out memory impairment. Vascular comorbidities, in-
cluding diabetes, hypertension, dyslipidemia, and white
matter abnormalities, have been related to MCI,38-48 and
it has been proposed that nonamnestic MCI in particu-
lar may be related to cerebrovascular disease.36,37,49 There
is increasing recognition of vascular comorbidity regard-
ing AD risk,50,51 and there is strong evidence relating the
MeDi to a lower risk of vascular risk factors such as dys-
lipidemia,52,53 hypertension,52-55 and coronary heart dis-
ease.3,53,56,57 Therefore, the stronger effect of the MeDi for
non-memory-impaired MCI conversion rates to AD may
relate to underlying vascular mechanisms. Neverthe-
less, nonvascular biological mediating mechanisms (ie,
metabolic, oxidative, and inflammatory) may also me-
diate the epidemiological MeDi-MCI associations.4
Both MCI and the MeDi have been associated with
metabolic abnormalities. Mild cognitive impairment has
been linked to dysregulation of glucose and insulin ho-
meostasis58-62 and diabetes.38-42 At the same time, accord-
ing to the vast majority of the literature (but see the ar-
ticles by Ambring et al63 and Michalsen et al64), higher
adherence to the MeDi seems to improve carbohydrate
metabolism, and in interventional studies it has been as-
sociated with significant reductions in plasma glucose lev-
els,53,55 serum insulin levels, and insulin resistance.55,65
Oxidative stress could be another biological mecha-
nism relating MCI and the MeDi. Higher oxidative stress
has been clearly invoked in MCI.66-71 Complex phenols
and many other substances with important antioxidant
properties such as olive oil,72,73 wine, fruits and veg-
etables, vitamin C, vitamin E, and carotenoids74-79 are
found in high concentrations in the typical components
of the MeDi.80 Typical Mediterranean meals81 or meals
rich in typical Mediterranean food elements82,83 have been
shown to increase enzymes with antioxidant properties
such as paroxonase and plasma carotenoids.81 Interven-
tion studies with Mediterranean-type foods have indi-
cated significant reductions of markers of oxidative stress
such as isoprostanes.80,84
Finally, the protective effect of the MeDi for MCI may
be mediated via inflammatory pathways. Links between
MCI and higher inflammatory states have been demon-
strated.85-89 Two small studies reported no effect of the
MeDi on inflammatory markers such as C-reactive pro-
tein63,64 or interleukin 6.63 Higher adherence to the MeDi
has been associated with lower levels of C-reactive pro-
tein in multiple large observational52,90,91 and interven-
tional55,81 studies. As another example, tyrosol and caf-
feic acid, both found in extra-virgin olive oil and wine
(which are essential components of the MeDi), have been
shown to significantly reduce interleukin 6 production
from peripheral blood mononuclear cells of healthy vol-
unteers.92 Higher adherence to the MeDi has been asso-
ciated with lower interleukin 6 levels in both observa-
tional52,91 and interventional55 studies. Higher adherence
to the MeDi is in general associated with significant re-
ductions in a series of other inflammatory markers in-
cluding white blood cell counts and others.52
The potentially beneficial effect of the MeDi may be
the result of some of its individual food components. For
example, potentially beneficial effects for MCI or MCI
conversion to AD have been reported for alcohol,7,11 fish,10
polyunsaturated fatty acids10,11 (also for age-related cog-
nitive decline8), and lower levels of saturated fatty ac-
ids.10 Interestingly, in other studies, alcohol,7,12 polyun-
saturated fatty acids,6 or other nutrients such as vitamin
E93,94 have failed to be associated with protection for MCI
or MCI conversion to AD. Differences in the definition
of the outcome (MCI [objective cognitive cutoffs in dif-
ferent cognitive domainsmemory complaintabsence
of functional impairmentabsence of dementia] vs age-
related cognitive decline [only a particular cognitive cut-
off on a summary cognitive score such as the Mini-
Mental State Examination]) may partly account for the
discrepancies. Nevertheless, it is also possible that a com-
posite dietary pattern such as the MeDi may better cap-
ture nutritional dimensions that may be missed by single
nutrients (ie, potential additive and interactive effects
among nutritional components).
Although Hispanic subjects reported higher adher-
ence to the MeDi, they also have higher risks for MCI14
and AD.95 A particular ethnic group may have a mixture
of multiple protective and risk factors, the overall inter-
action of which determines the probability of develop-
ing a complex disease such as AD. For example, the His-
panic subjects may be placed at risk by their low education
and SORL1 gene status,96 whereas they may be pro-
tected by their dietary habits and lack of a detrimental
effect of the APOE genotype.95 At the same time, there
may be multiple other genes or behavioral traits unique
to the Hispanic subjects that may contribute to AD, re-
sulting in an overall higher risk in this ethnic group.
Study limitations regarding duration of follow-up and
demographics of subjects with either missing data for MCI
diagnostic assignment or missing follow-up have been dis-
cussed in detail in a previous article.14 Subjects excluded
from the present analyses because of missing dietary in-
formation had slightly lower cognitive performance, were
less educated, and had higher BMIs. Worse cognition and
a lower educational level indicate that these subjects were
more likely at higher risk for MCI and AD, but a higher
BMI indicates the opposite. Most important, these sub-
jects did not differ in most other characteristics. Potential
confounding from associations between adherence to the
MeDi and total caloric intake or ethnicity was addressed
by adjusting for these factors. Limitations relating to the
construction of the MeDi score (eg, use of an a priori di-
etary pattern score, equal weighing of underlying food cat-
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egories, and underestimation of total food and caloric in-
take) have been discussed in detail in previous articles.4,5
All of the models were adjusted for total caloric intake
(largely determined by metabolic efficiency, BMI, and physi-
cal activity). Given that metabolic efficiency is unmeasur-
able and that BMI was included as a covariate, when we
adjust for total caloric intake we essentially adjust for physi-
cal activity.30 Nevertheless, we cannot completely ex-
clude the possibility that physical activity may partly ac-
count for some of the effect of the MeDi. Although
adherence to the MeDi was not related to education or to
the overall level of medical comorbidities in our data, it is
possible that a better diet is related to higher socioeco-
nomic status or to other habits or characteristics related
to better health. Therefore, despite adjusting for multiple
variables, the study is observational and we cannot com-
pletely exclude residual confounding or “healthy person
bias” (that can be addressed only via the randomization
of an interventional study). In conservative (for the study
size and follow-up) models using age as the timing vari-
able of survival models, the associations were signifi-
cantly attenuated. Although age was not related to the
MeDi, we cannot completely exclude the possibility that
the noted associations are confounded by age. Finally, be-
cause the current study started before the concept of MCI
was developed, diagnosis of MCI was retrospectively ap-
plied in data that had already been collected (rather than
being applied synchronously with the diagnostic consen-
sus conference).
Because of the synchronous timing of dietary and cog-
nitive assessments and the relatively short follow-up, we
cannot completely exclude reverse causation (ie, di-
etary habits being affected by cognitive status rather than
the opposite). Nevertheless, in 2 previous articles4,5 using
a subset of 390 subjects with repeated (2-4) dietary as-
sessments over a course of approximately 8 (and up to
13) years, we demonstrated that adherence to the MeDi
is remarkably stable over time. Therefore, we consider
it more likely that the reported MeDi adherence reflects
our population’s longstanding dietary habits. Finally, be-
cause this is the first study to our knowledge demon-
strating an association between the MeDi and MCI, rep-
lication in other populations is necessary.
Confidence in our findings is strengthened by the fol-
lowing factors. The study is community-based and the
population is multiethnic, increasing the external valid-
ity of the findings. Dietary data were collected with an in-
strument that has been previously validated and has been
used widely in epidemiological studies. The diagnosis of
MCI and AD took place in a university hospital with ex-
pertise in such disorders and was based on comprehen-
sive assessments and standard research criteria. The pa-
tients were followed up prospectively at relatively short
intervals. Measures for multiple potential confounders were
carefully recorded and adjusted for in the analyses.
Overall, the effects of dietary habits in MCI have not
been adequately explored. These results provide sup-
port that MeDi-type habits may affect risk for both de-
veloping MCI and MCI conversion to AD. Possible bio-
logical mechanisms underlying this association remain
to be investigated. Exploration of such mechanisms and
potential future interventional studies will provide a more
complete and convincing picture of the conceivably im-
portant role of a healthy diet in the risk of cognitive im-
pairment and AD.
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